{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T13:27:55Z","timestamp":1772026075445,"version":"3.50.1"},"reference-count":32,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the Korea Health Technology R&D Project","award":["RS-2022-KH129464"],"award-info":[{"award-number":["RS-2022-KH129464"]}]},{"name":"the Patient-Centered Clinical Research Coordinating Center","award":["RS-2020-KH095267"],"award-info":[{"award-number":["RS-2020-KH095267"]}]},{"name":"Hallym University Research Fund"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Several receptors have received considerable attention as therapeutic targets in gastric cancer (GC), and numerous receptor inhibitors have been developed. However, the development of novel gastric cancer therapeutics is time-consuming. Therefore, this study aimed to identify drugs effective against gastric cancer from existing anticancer agents originally developed for other malignancies. In this study, the cancer-related genomic profiles of 286 genes were analyzed in 14 gastric cancer cell lines using targeted DNA sequencing, and these cell lines were utilized as models to evaluate the efficacy of 35 anticancer drugs. The 14 cell lines were assessed for 286 gene alterations, copy number variations, amplification of 14 gastric cancer-related therapeutic targets, and sensitivity to 35 drugs. p-MET and MET were overexpressed in the SNU5, SNU620, MKN45, and Hs746T cell lines, while p-EGFR was overexpressed in the NCI-N87 cell line. FGFR2 overexpression was observed in the Kato III and SNU16 cell lines. TGF\u03b2R1 was overexpressed in the MKN7 cell line. HER2 and CDK12 were overexpressed in the NCI-N87 and MKN7 cell lines. PD-L1 overexpression was detected in the Hs746T and MKN7 cell lines. CD44 was overexpressed in the SNU5 and Hs746T cell lines and CLDN18 overexpression was observed in the MKN7 cell line. Well-characterized gastric cancer cell lines are essential for drug development research. This study provides a framework for selecting cell lines that are responsive to each of the 35 anticancer drugs and elucidating their underlying therapeutic mechanisms through follow-up studies. Ultimately, clinical studies are required to confirm the therapeutic efficacy of the selected drugs.<\/jats:p>","DOI":"10.3390\/ijms27052133","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T12:35:17Z","timestamp":1772022917000},"page":"2133","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of the Efficacy of 35 Anticancer Drugs According to Genomic Profiling and Biological Characteristics of 14 Gastric Cancer Cell Lines"],"prefix":"10.3390","volume":"27","author":[{"given":"Sung-Hwa","family":"Sohn","sequence":"first","affiliation":[{"name":"Hallym Translational Research Institute, Hallym University Sacred Heart Hospital, Anyang-si 14066, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hee Jung","family":"Sul","sequence":"additional","affiliation":[{"name":"Hallym Translational Research Institute, Hallym University Sacred Heart Hospital, Anyang-si 14066, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2360-5160","authenticated-orcid":false,"given":"Bum Jun","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University Medical Center, Hallym University College of Medicine, Anyang-si 14068, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dae Young","family":"Zang","sequence":"additional","affiliation":[{"name":"Hallym Translational Research Institute, Hallym University Sacred Heart Hospital, Anyang-si 14066, Republic of Korea"},{"name":"Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University Medical Center, Hallym University College of Medicine, Anyang-si 14068, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"303","DOI":"10.4143\/crt.2018.143","article-title":"The Community of Population-Based Regional Cancer Registries. Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2015","volume":"50","author":"Jung","year":"2018","journal-title":"Cancer Res. Treat."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2147\/CMAR.S149619","article-title":"Gastric cancer: Epidemiology, prevention, classification, and treatment","volume":"10","author":"Sitarz","year":"2018","journal-title":"Cancer Manag. Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1039\/C5MB00306G","article-title":"Protein localization vector propagation: A method for improving the accuracy of drug repositioning","volume":"11","author":"Yeu","year":"2015","journal-title":"Mol. Biosyst."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.7150\/ijbs.24612","article-title":"Review of Drug Repositioning Approaches and Resources","volume":"14","author":"Xue","year":"2018","journal-title":"Int. J. Biol. Sci."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.pharmthera.2013.12.014","article-title":"The Met receptor tyrosine kinase: A key player in oncogenesis and drug resistance","volume":"142","author":"Maroun","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/bjc.2011.603","article-title":"FGFR2 gene amplification and clinicopathological features in gastric cancer","volume":"106","author":"Matsumoto","year":"2012","journal-title":"Br. J. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Arienti, C., Pignatta, S., and Tesei, A. (2019). Epidermal Growth Factor Receptor Family and its Role in Gastric Cancer. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.01308"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/annonc\/mdi064","article-title":"Amplification of HER-2 in gastric carcinoma: Association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab","volume":"16","author":"Tanner","year":"2005","journal-title":"Ann. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1158\/1535-7163.MCT-06-0628","article-title":"Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo","volume":"6","author":"Lang","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Sohn, S.H., Sul, H.J., Kim, B.J., and Zang, D.Y. (2022). Responses to the Tepotinib in Gastric Cancers with MET Amplification or MET Exon 14 Skipping Mutations and High Expression of Both PD-L1 and CD44. Cancers, 14.","DOI":"10.3390\/cancers14143444"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.18632\/oncotarget.718","article-title":"MET amplification as a potential therapeutic target in gastric cancer","volume":"4","author":"Kawakami","year":"2013","journal-title":"Oncotarget"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nrc2780","article-title":"Fibroblast growth factor signalling: From development to cancer","volume":"10","author":"Turner","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1038\/sj.onc.1210477","article-title":"The oncogene HER2: Its signaling and transforming functions and its role in human cancer pathogenesis","volume":"26","author":"Moasser","year":"2007","journal-title":"Oncogene"},{"key":"ref_14","first-page":"2916","article-title":"Detection of prostate cancer related copy number variations with SNP genotyping array","volume":"17","author":"Wang","year":"2013","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/gm62","article-title":"Copy number variations and cancer","volume":"1","author":"Shlien","year":"2009","journal-title":"Genome Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"247","DOI":"10.7150\/jca.10747","article-title":"Non-invasive Analysis of Genomic Copy Number Variation in Patients with Hepatocellular Carcinoma by Next Generation DNA Sequencing","volume":"6","author":"Xu","year":"2015","journal-title":"J. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e2415445","DOI":"10.1001\/jamanetworkopen.2024.15445","article-title":"Costs of Drug Development and Research and Development Intensity in the US, 2000\u20132018","volume":"7","author":"Sertkaya","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/jphp.13273","article-title":"Drug repositioning: A brief overview","volume":"72","author":"Jourdan","year":"2020","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12935-025-03655-8","article-title":"A literature review of recent advances in gastric cancer treatment: Exploring the cross-talk between targeted therapies","volume":"25","author":"Panahizadeh","year":"2025","journal-title":"Cancer Cell Int."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.3748\/wjg.v12.i21.3297","article-title":"Role of receptor tyrosine kinases in gastric cancer: New targets for a selective therapy","volume":"12","author":"Becker","year":"2006","journal-title":"World J. Gastroenterol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Hashimoto, I., and Oshima, T. (2022). Claudins and Gastric Cancer: An Overview. Cancers, 14.","DOI":"10.3390\/cancers14020290"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Agnarelli, A., Vella, V., Samuels, M., Papanastasopoulos, P., and Giamas, G. (2022). Incorporating Immunotherapy in the Management of Gastric Cancer: Molecular and Clinical Implications. Cancers, 14.","DOI":"10.3390\/cancers14184378"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13045-019-0718-5","article-title":"Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy","volume":"12","author":"Qin","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","article-title":"Small molecules in targeted cancer therapy: Advances, challenges, and future perspectives","volume":"6","author":"Zhong","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"6913","DOI":"10.1007\/s12010-023-04436-7","article-title":"CDK12 Promotes the Proliferation, Migration, and Angiogenesis of Gastric Carcinoma via Activating the PI3K\/AKT\/mTOR Signaling Pathway","volume":"195","author":"Gao","year":"2023","journal-title":"Appl. Biochem. Biotechnol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrc2853","article-title":"TGFbeta signalling: A complex web in cancer progression","volume":"10","author":"Ikushima","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"108221","DOI":"10.1016\/j.compbiomed.2024.108221","article-title":"Molecular insights into gastric cancer: The impact of TGFBR2 and hsa-mir-107 revealed by microarray sequencing and bioinformatics","volume":"172","author":"Jin","year":"2024","journal-title":"Comput. Biol. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"7624","DOI":"10.1158\/1078-0432.CCR-08-1547","article-title":"Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development","volume":"14","author":"Sahin","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"24269","DOI":"10.18632\/oncotarget.8169","article-title":"PD-L1 is an independent prognostic predictor in gastric cancer of Western patients","volume":"7","author":"Boger","year":"2016","journal-title":"Oncotarget"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/his.12202","article-title":"Expression of moesin and CD44 is associated with poor prognosis in gastric adenocarcinoma","volume":"63","author":"Jung","year":"2013","journal-title":"Histopathology"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Hou, W., Kong, L., Hou, Z., and Ji, H. (2022). CD44 is a prognostic biomarker and correlated with immune infiltrates in gastric cancer. BMC Med. Genom., 15.","DOI":"10.1186\/s12920-022-01383-w"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Sohn, S.H., Sul, H.J., Kim, B.J., and Zang, D.Y. (2024). Comparison of Tepotinib, Paclitaxel, or Ramucirumab Efficacy According to the Copy Number or Phosphorylation Status of the MET Gene: Doublet Treatment versus Single Agent Treatment. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25031769"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/5\/2133\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T12:38:41Z","timestamp":1772023121000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/5\/2133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":32,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["ijms27052133"],"URL":"https:\/\/doi.org\/10.3390\/ijms27052133","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]}}}